Merck KGaA takes ‘balanced risk’ with Cyclica’s AI platform

10:27 EST 12 Dec 2018 | Outsourcing-Pharma

Merckâs agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclicaâs AI protein screening platform.

Original Article: Merck KGaA takes ‘balanced risk’ with Cyclica’s AI platform


More From BioPortfolio on "Merck KGaA takes ‘balanced risk’ with Cyclica’s AI platform"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...